Previous Page  210 / 320 Next Page
Information
Show Menu
Previous Page 210 / 320 Next Page
Page Background

614

12. Carlier M, Stove V, Wallis SC, De Waele JJ, Verstraete AG, Lipman

J, et al. Assays for therapeutic drug monitoring of beta-lactam

antibiotics: A structured review. Int J Antimicrob Agents.

2015;46(4):367–75.

13. Dulhunty JM, Roberts J a, Davis JS, Webb S a R, Bellomo R,

Gomersall C, et al. Continuous infusion of beta-lactam antibiotics

in severe sepsis: a multicenter double-blind, randomized

controlled trial. Clin Infect Dis. 2013;56(2):236–44.

14. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts J a. Does Beta-

lactam Pharmacokinetic Variability in Critically Ill Patients Justify

Therapeutic Drug Monitoring? A Systematic Review. Annals of

Intensive Care; 2012;2(1):35.

15. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R,

Hope WW. Therapeutic drug monitoring (TDM) of antifungal

agents: Guidelines from the british society for medical mycology.

J Antimicrob Chemother. 2014;69(5):1162–76.

16. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM,

et al. Surviving sepsis campaign: international guidelines for

management of severe sepsis and septic shock: 2012. Crit Care

Med. 2013;39(2):165–228.

17. Tomlin M. Pharmacology & Pharmacokinetics. A basic reader.

London: Springer; 2009. 1-170 p.

18. Bonate P. Pharmacokinetic - Pharmacodynamic Modeling and

Simulation. Second Edition. London: Springer; 2011. 618 p.

19. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS,

Kauffman RE. Developmental pharmacology--drug disposition,

action, and therapy in infants and children. N Engl J Med.

2003;349(12):1157–67.

20. Aymanns C, Keller F, Maus S, Hartmann B, Czock D. Review on

pharmacokinetics and pharmacodynamics and the aging kidney.

Clin J Am Soc Nephrol. 2010;5(2):314–27.

21. Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of kidney

function on drug kinetics and dosing in neonates, infants, and

children. Clin Pharmacokinet. 2015;54(12):1183–204.

22. Escobar L, Gai MN, Regueira T, Andresen M. Consideraciones

farmacocinéticas en el paciente crítico. Rev Med Chil.

2012;780–8.

23. Varghese JM, Roberts JA, Lipman J. Pharmacokinetics and

pharmacodynamics in critically ill patients. Curr Opin

Anaesthesiol. 2010;23:472–8.

24. Cheymol G. Effects of obesity on pharmacokinetics implications

for drug therapy. Clin Pharmacokinet. 2000;39(3):215–31.

25. Stepensky D. Prediction of drug disposition on the basis of its

chemical structure. Clin Pharmacokinet. 2013;52(6):415–31.

26. Greenberg E, Saad N. Drug dosage adjustment using renal

estimation equations: A review of the literature. Hosp Pharm.

2009;44(7):577–84.

27. FDA. Guidance for Industry Bioanalytical Method Validation.

2001.

28. Peters FT, Drummer OH, Musshoff F. Validation of new methods.

Forensic Sci Int. 2007;165(2-3):216–24.

29. EMA. Guideline on bioanalytical method validation [Internet].

Committee for Medicinal Products for Human Use (CHMP). 2011.

Available from:

www.ema.europa.eu

30. Adaway JE, Keevil BG. Therapeutic drug monitoring and LC-MS/

MS. J Chromatogr B. 2012;883-884:33–49.

31. Pauwels S, Allegaert K. Therapeutic drug monitoring in neonates.

Arch Dis Child. 2016;1:377–81.

32. Patsalos PN, Berry DJ. Therapeutic drugmonitoring of antiepileptic

drugs by use of saliva. Ther Drug Monit. 2013;35(1):4–29.

[REV. MED. CLIN. CONDES - 2016; 27(5) 605-614]